Anaqua macht ausländische Patentanmeldungen zu einem strategischen Vorteil für IP-Profis
April 18, 2024 07:00 ET
|
Anaqua
BOSTON / MÜNCHEN, April 18, 2024 (GLOBE NEWSWIRE) -- Anaqua, der führende Anbieter von Innovations- und IP-Management-Technologien, kündigt die Weiterentwicklung seines Angebots für...
アナクアが外国特許出願を戦略的アドバンテージに変える 機能・サービス強化を発表
April 18, 2024 07:00 ET
|
Anaqua
ボストン, April 18, 2024 (GLOBE NEWSWIRE) --...
Anaqua transforme l’extension de brevets à l’international en avantage stratégique pour les professionnels de la PI
April 18, 2024 07:00 ET
|
Anaqua
BOSTON, 18 avr. 2024 (GLOBE NEWSWIRE) -- Anaqua, le leader des technologies de gestion de la propriété intellectuelle (PI) pour les entreprises, les conseils et les administrations, annonce...
Anaqua Transforms Foreign Patent Filing into a Strategic Advantage for Intellectual Property Professionals
April 18, 2024 07:00 ET
|
Anaqua
Anaqua revolutionizes IP management with enhanced Foreign Filing in AQX®, empowering swift global protection decisions.
Edmonton Unlimited Welcomes New CEO, Tom Viinikka
April 17, 2024 10:30 ET
|
Edmonton Unlimited
Edmonton, Alberta, April 17, 2024 (GLOBE NEWSWIRE) -- Edmonton Unlimited is pleased to announce the appointment of Tom Viinikka as its new CEO, empowering the organization to scale and deliver on...
EZLynx Launches Industry-First Quote By Text Innovation
April 17, 2024 09:00 ET
|
EZLynx
Lewisville, TX., April 17, 2024 (GLOBE NEWSWIRE) -- EZLynx, an Applied company, today announced its latest personal lines rating innovation, Quote By Text, an insurance industry-first quoting...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
April 15, 2024 14:00 ET
|
Novartis Pharma AG
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare...
Canadian innovation taking plant-protein nutrition to new heights
April 15, 2024 13:00 ET
|
Protein Industries Canada
Toronto, Ont., April 15, 2024 (GLOBE NEWSWIRE) -- Today, Protein Industries Canada held a tasting and networking event to celebrate the launch of its latest project announcement: A collaborative...